Alethia Biotherapeutics (Canada)
Alethia is currently focusing on cancer-associated epithelial-to-mesenchymal transition with its AB-16B5 monoclonal antibody, a clinical stage EMT inhibitor to prevent chemotherapy resistance and metastatic tumour invasion
Basic Information
- Category: business
- Website: http://alethiabio.com/
Documented Facts
- Inception (Wikidata): 2002 (Source 2: Wikidata Q30283638, revision 2474196669)
- Country (Wikidata; date unspecified): Canada (Source 2: Wikidata Q30283638, revision 2474196669; Source 3: Wikidata label: Q16, revision 2555105353)
- Official website (Wikidata; date unspecified): http://alethiabio.com/ (Source 2: Wikidata Q30283638, revision 2474196669)
Evidence and Sources
- Alethia Biotherapeutics (Canada) — Official Website (official)
- Wikidata Q30283638, revision 2474196669 (knowledge-base)
- Wikidata label: Q16, revision 2555105353 (knowledge-base)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Alethia Biotherapeutics (Canada).
- Canonical profile: https://brandsource.ai/brands/alethia-biotherapeutics-canada
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/alethia-biotherapeutics-canada/json-ld
- Citation profile API: https://brandsource.ai/api/brands/alethia-biotherapeutics-canada/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Alethia is currently focusing on cancer-associated epithelial-to-mesenchymal transition with its AB-16B5 monoclonal antibody, a clinical stage EMT inhibitor to prevent chemotherapy resistance and metastatic tumour invasion
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.